

# Meta-analysis demonstrates association between *TLR* polymorphisms and rheumatoid arthritis

Y.H. Lee<sup>1</sup>, S.-C. Bae<sup>2</sup> and G.G. Song<sup>1</sup>

<sup>1</sup>Division of Rheumatology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Korea <sup>2</sup>Division of Rheumatology, Department of Internal Medicine, Medical Center, Hanyang University, Seoul, Korea

Corresponding author: Y.H. Lee E-mail: lyhcgh@korea.ac.kr

Genet. Mol. Res. 12 (1): 328-334 (2013) Received March 7, 2012 Accepted August 3, 2012 Published February 7, 2013 DOI http://dx.doi.org/10.4238/2013.February.7.2

**ABSTRACT.** We investigated whether Toll-like receptor (*TLR*) polymorphisms confer susceptibility to rheumatoid arthritis and whether they influence clinical characteristics of rheumatoid arthritis. Studies were considered relevant for our meta-analysis if at least two comparisons of an issue were available. Eleven studies with 2078 patients with rheumatoid arthritis and 2581 controls were included, encompassing European and Asian studies. Meta-analysis of three European studies showed no significant association between the TLR4 Asp299Gly (rs4986790) polymorphism and rheumatoid arthritis (odds ratio = 0.897, 95% confidence interval = 0.734-1.096, P = 0.289). One Turkish study showed a significant difference between TLR9 rs187084 allele frequencies and rheumatoid arthritis patients and controls, while another study revealed a significant association between rheumatoid factor and TLR8 rs5741883. A Korean study on the numbers of guanine-thymine [(GT)] repeats in intron II of the TLR2 gene found a significantly higher S-allele frequency in rheumatoid arthritis patients than in controls (30.3 vs 23.0%). Overall findings for the meta-analysis

Genetics and Molecular Research 12 (1): 328-334 (2013)

including all the studies conclude that *TLR* polymorphism is associated with development and clinical characteristics of rheumatoid arthritis in Asian and Middle East populations.

Key words: Toll-like receptor; Polymorphism; Rheumatoid arthritis

#### **INTRODUCTION**

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects predominantly synovial joints, causes significant morbidity, and shortens life expectancy. RA affects up to 1% of the world population. Although the etiology of RA is undetermined, a genetic component has been established, and human leukocyte antigen class II molecules are the most powerful genetic factors identified to date (Wordsworth and Bell, 1991). However, this association accounts for only one-third of the genetic susceptibility, and non-human leukocyte antigen genes are also known to be involved (Deighton et al., 1989).

Toll-like receptors (TLRs) constitute a family of transmembrane proteins expressed by various cell types, including immune cells, to identify pathogens and initiate inflammatory signaling pathways (Takeda et al., 2003). Stimulation of the TLR pathway culminates in nuclear factor  $\kappa$ B activation and the transcription of immune response genes (Drexler and Foxwell, 2010). To date, at least 10 human TLRs have been discovered; they recognize a variety of molecules, including lipoproteins, flagellin, and viral RNA or DNA (Roelofs et al., 2008). Furthermore, the administration of endogenous RNA or DNA has been shown to activate TLRs and induce autoimmune reactions (Hurst and von Landenberg, 2008). Based on the immune-regulating and immune-response-initiating effects of TLRs, they are considered candidate genes for RA.

Several studies have examined the potential contributions of *TLR* polymorphisms to RA, but the results have been variable (Kilding et al., 2003; Radstake et al., 2004; Sanchez et al., 2004; Kuuliala et al., 2006; Lee et al., 2006; Kang and Lee, 2007; Sheedy et al., 2008; Jaen et al., 2009; Enevold et al., 2010; Zheng et al., 2010; Etem et al., 2011). In the present study, we used a systematic review approach to explore whether *TLR* polymorphisms confer susceptibility to RA or are related to its clinical characteristics.

## **MATERIAL AND METHODS**

#### Identification of eligible studies and data extraction

A MEDLINE search was performed for studies published before October 2010 that examined associations between *TLR* polymorphisms and RA with respect to susceptibility or disease severity. Combinations of key words such as Toll-like receptor, *TLR*, polymorphism, rheumatoid arthritis, and RA were entered as both medical subject headings and text words. References in identified studies were also examined to identify additional studies not indexed by MEDLINE. Studies on genetic or clinical associations that determined the distributions of *TLR* alleles in RA patients or controls were eligible for inclusion in our systematic review. Meta-analysis was performed if at least 2 comparisons of an issue were available.

Genetics and Molecular Research 12 (1): 328-334 (2013)

Y.H. Lee et al.

### RESULTS

#### Studies included in the meta-analysis

Eleven studies met the study inclusion criteria (Kilding et al., 2003; Radstake et al., 2004; Sanchez et al., 2004; Kuuliala et al., 2006; Lee et al., 2006; Kang and Lee, 2007; Sheedy et al., 2008; Jaen et al., 2009; Enevold et al., 2010; Zheng et al., 2010; Etem et al., 2011 (Table 1). These studies involved 2078 patients with RA and 2581 controls. Eight studies were case-control studies (Kilding et al., 2003; Radstake et al., 2004; Sanchez et al., 2004; Lee et al., 2006; Kang and Lee, 2007; Sheedy et al., 2008; Zheng et al., 2010; Etem et al., 2011), two were case-only studies (Kuuliala et al., 2006; Enevold et al., 2010), and one was a family study (Jaen et al., 2009). Relevant features of the studies included in this systematic review are provided in Table 1.

## Association between TLR polymorphisms and RA susceptibility and clinical findings

Etem et al. (2011) found a significant difference between *TLR9* rs187084 allele frequencies in Turkish RA patients and controls (P = 0.003) but not between *TLR3* rs3775290 and *TLR10* rs4129009 polymorphisms. No associations were found between disease activity score 28 (DAS28) or autoantibodies and *TLR3*, 9, or 10 polymorphisms. Enevold et al. (2010) genotyped 22 polymorphisms in *TLR2*, 3, 4, 5, 7, 8, and 9 in 319 RA patients to investigate the relationship between these TLR polymorphisms and disease phenotype and RA severity. A moderate association was found between RF positivity and TLR8 rs5741883 (P = 0.001), but no other *TLR* polymorphism was found to be associated with the clinical characteristics of RA. Lee et al. (2006) counted numbers of guanine-thymine repeats in intron II of the *TLR2* gene in 183 Korean RA patients and 148 controls. In this study, alleles were classified as 12-16 GT repeats (S allele) and 17-28 repeats (L allele), and the results revealed that the S allele had a frequency in RA patients that was significantly higher than that in controls (30.3 *vs* 23.0%, P = 0.03).

#### Meta-analysis of the TLR4 Asp299Gly (rs4986790) polymorphism and RA

Six studies (4 European and 2 Asian studies), including 5 case-control studies (Kilding et al., 2003; Radstake et al., 2004; Kang and Lee, 2007; Sheedy et al., 2008; Zheng et al., 2010) and 1 case-only study (Kuuliala et al., 2006), addressed the *TLR4* Asp299Gly (rs4986790) polymorphism. Both *TLR4* Asp299Gly (rs4986790) and Thr399IIe (rs4986791) were investigated in the 2 Asian studies (1 Korean and 1 Chinese), but these polymorphisms were not detected (Kang and Lee, 2007; Zheng et al., 2010).

Owing to the limited number of studies on polymorphisms, meta-analysis was performed only on the *TLR4* Asp299Gly (rs4986790) polymorphism. Three studies examined the association between this polymorphism and RA, and all were conducted in Europe (Kilding et al., 2003; Radstake et al., 2004; Sheedy et al., 2008). One study identified a difference in genotype frequency between patients and controls (P = 0.025) (Radstake et al., 2004), but the other 2 found no significant association between this polymorphism and RA (Kilding et al., 2003; Sheedy et al., 2008). Furthermore, we also failed to find an association between this polymorphism and RA in Europeans through meta-analysis (odds ratio = 0.897, 95% confidence interval = 0.734-1.096, P = 0.289; Figure 1). In terms of clinical findings, the 3 European studies included in the meta-analysis found no association between this polymorphism and clinical characteristics.

Genetics and Molecular Research 12 (1): 328-334 (2013)

TLR polymorphisms and rheumatoid arthritis

Etem et al. (2011)Turkey (T)1001007LR3: rs3775290, TLR9: rs177590, TLR9: rs177590, TLR9: rs177590, TLR9: rs177084 (P = 0.003)Personality traits, DAS28, automatibody: NSZhene get al. (2010)China (A)213247TLR4: Asp299Gty (rs4986790), TLR9: rs1737191, rs4987790), None polymorphisms detectedNAEnervold et al. (2010)Netherlands (E)319022 SNPs in TLR2: s, 4, 5, 7, 8NAAmoderate association betweenRevold et al. (2010)France (E)100°0TLR4: rs27315191, rs4986790, rs1554973, NSNaAmoderate association betweenSheedy et al. (2003)France (E)100°0TLR4: rs27315191, rs4986790, rs1554973, NSNaAmoderate association betweenSheedy et al. (2006)Evera (A)964961TLR4: rs273191, rs4986790, rs1554973, NSNaAmoderate association betweenRang and Lee (2007)Korea (A)183148TLR4: rs273191, rs4986790, rs1554973, NSNaRF, anti-CCP, roSins: NSKunilala et al. (2006)Korea (A)183148TLR4: Asp299Gty (rs4986790), rs1554973, NoNaAmoderate association with rapid responseKunilala et al. (2004)Netherlands (E)282314TLR4: Asp299Gty (rs4986790), rn13991le (rs4986790), NaNaAmoderate association with rapid responseKunilala et al. (2004)Netherlands (E)282314TLR4: Asp299Gty (rs4986790), rn13991le (rs4986790), NaNaAmoderate association with rapid responseKunilala et al. (2004)Netherlands (E)282314TLR4: Asp299Gty (rs4986790), rn1	Author (year)	Country (ethnicity)	RA	Control	TLR polymorphisms	Susceptibility	Clinical findings
Zheng et al. (2010)China (A)213247 $TLR4$ : Asp29Giy (rs4986790), Thr390lle (rs4986790)None polymorphisms detectedNAEnevold et al. (2010)Neherlands (E)3190 $22SNPs$ in $TLR2$ , $3, 4, 5, 7, 8$ None polymorphisms detectedNAEnevold et al. (2009)France (E)100°0 $TLR4$ : rs5743618, rs5743594; $TLR2$ : rs3804099,NSRF positivity and $TLR8$ : rs5741883Iaen et al. (2009)France (E)100°0 $TLR4$ : rs5743610, $TLR4$ : rs574310, $TLR4$ : rs5295019, (rs4986790), $TL34976790$ , $TLR4$ : rs5295019, (rs4986790), $TLR49000000000000000000000000000000000000$	Etem et al. (2011)	Turkey (T)	100	100	TLR3: rs3775290; TLR9: rs187084; TLR10: rs4129009	<i>TLR9</i> : $rs187084$ (P = 0.003)	Personality traits, DAS28, autoantibodv: NS
Enevold et al. (2010)   Netherlands (E)   319   0   22 SNPs in <i>TLR2</i> , <i>3, 4, 5, 7, 8</i> NA   A modera ssociation between RF positivity and <i>TLR3</i> : rs5741883     Jaen et al. (2009)   France (E)   100°   0 <i>TLR4</i> : rs2735191, rs4986790, rs1554973;   NS   RF, anti-CCP, erosions: NS     Sheedy et al. (2009)   France (E)   00°   0 <i>TLR4</i> : rs2735191, rs4986790, rs1554973;   NS   RF, anti-CCP, erosions: NS     Sheedy et al. (2008)   UK (E)   964   961   7LR4: rs27930(); (rs4986790)   NS   RF, anti-CCP; erosions: NS     Kang and Lee (2007)   Korea (A)   183   148 <i>TLR4</i> : rs2790(); (rs4986790)   NA   Association with rapid response     Kuuliala et al. (2006)   Finland (E)   169   0 <i>TLR4</i> : rs2990(); (rs4986790)   NA   Association with rapid response     Kuuliala et al. (2004)   Netherlands (E)   232   314 <i>TLR4</i> : rs2990(); (rs4986790)   NA   Association with rapid response     Sanchezet al. (2004)   Netherlands (E)   282   314 <i>TLR4</i> : rs2990(); (rs4986790)   NA   Association (P = 0.02)   DASS18(P = 0.02)     Sanc	Zheng et al. (2010)	China (A)	213	247	TLR4: Asp299Gly (rs4986790), Thr399Ile (rs4986791)	None polymorphisms detected	NA
Iace et al. (2009)France (E)100°0TLR1: rs5743618, rs5743594; TLR2: rs3804099,NSRF, anti-CCP, erosions: NSSheedy et al. (2008)UK (E)964961TLR4: rs5743810, TLR9: rs373191NSRF, anti-CCP, erosions: NSSheedy et al. (2006)Korea (A)4480TLR4: rs929G19 (rs4986790)NSRF, anti-CCP, erosions: NSKang and Lee (2007)Korea (A)4480TLR4: Asp29G19 (rs4986790)NSRF, anti-CCP, erosions: NSKuuliala et al. (2006)Finland (E)1690TLR4: Asp29G19 (rs4986790)NASallele' (P = 0.03)Kuuliala et al. (2004)Netherlands (E)222314TLR4: Asp29G19 (rs4986790)NAAssociation with rapid responseRadstake et al. (2004)Netherlands (E)222314TLR4: Asp29G19 (rs4986790)NAAssociation (P = 0.025)DAS, IAAO, Shap score: NSSanchez et al. (2004)Netherlands (E)222314TLR4: Asp29G19 (rs4986790)NSAssociation (P = 0.025)DAS, IAAO, Shap score: NSSanchez et al. (2004)Spain (E)224199TLR4: Asp29G19 (rs4986790)NSDAS, IAAO, Shap score: NSSanchez et al. (2004)Netherlands (E)222314TLR4: Asp29G19 (rs4986790)NSDAS, IAAO, Shap score: NSSanchez et al. (2004)Netherlands (E)222314TLR4: Asp29G19 (rs4986790)NSDAS, IAAO, Shap score: NSSanchez et al. (2004)Netherlands (E)222314TLR4: Asp29G19 (rs4986790)NSDASSan	Enevold et al. (2010)	Netherlands (E)	319	0	22 SNPs in <i>TLR2</i> , <i>3</i> , <i>4</i> , 5, 7, 8	NA	A moderate association between RF positivity and <i>TLR8</i> : rs5741883
Isa4696480; 71.RA: rs2737191, rs4986790, rs1554973; TLR6: rs273810; 71.R9: rs2737191, rs4986790; rs1554973; TLR6: rs2734810; rr120: rs274380; rr120: rs274380; rs274380; rs254380; rs254380; rs254380; rs254380; rs254380; rs254380; rs254380; rs254380; rs254380; rs230410; rs230410; rs230410; rs30480; rs230410; rs230410; rs30480; rs230410; rs4986790; rs2004; rs4986790; rs224RF, anti-CCP: NSRadstake et al. (2004)Finland (E)169071.RA: rsp299Gly (rs4986790)NaRadstake et al. (2004)Netherlands (E)28231471.RA: rsp299Gly (rs4986790)Association (P = 0.025)Passociation with rapid responseRadstake et al. (2004)Netherlands (E)28231471.RA: rsp299Gly (rs4986790)NaAssociation (P = 0.025)Pasted epitope, RF, rheumatoidSanchez et al. (2004)Spain (E)22419971.RA: rsp299Gly (rs4986790)NsAssociation (P = 0.025)Pasted epitope, RF, rheumatoidSanchez et al. (2004)Spain (E)21287971.RA: rsp299Gly (rs4986790)NsShared epitope, RF, rheumatoidSanchez et al. (2004)Netherlands (E)28771.RA: rsp299Gly (rs4986790)NsShared epitope, RF, rheumatoidRidding et al. (2003)UK (E)21287971.RA: rsp299Gly (rs4986790)NsShared epitope; RF, rheumatoidFandel and relevanceN21287971.RA: rsp299Gly (rs4986790)NsShared epitope; RF, rheumatoidRole and relevanceNN </td <td>Jaen et al. (2009)</td> <td>France (E)</td> <td><math>100^{a}</math></td> <td>0</td> <td>TLRI: rs5743618, rs5743594; TLR2: rs3804099,</td> <td>NS</td> <td>RF, anti-CCP, erosions: NS</td>	Jaen et al. (2009)	France (E)	$100^{a}$	0	TLRI: rs5743618, rs5743594; TLR2: rs3804099,	NS	RF, anti-CCP, erosions: NS
Sheedy et al. (2008) UK (E) 964 961 <i>TLR4</i> : Asp299Giy (rs4986790) NS RF, anti-CCP: NS Kan and Lee (2007) Korea (A) 44 80 <i>TLR4</i> : Asp299Giy (rs4986790), Thr399Ile (rs4986791) None polymorphisms detected NA Lee et al. (2006) Finland (E) 169 0 <i>TLR4</i> : Asp299Giy (rs4986790) NA Saliele <sup>6</sup> (P = 0.03) NA Association with rapid response NA Kaster et al. (2004) Spain (E) 169 0 <i>TLR4</i> : Asp299Giy (rs4986790) NS NA Association (P = 0.03) NA Association with rapid response NA Kaster et al. (2004) Spain (E) 222 314 <i>TLR4</i> : Asp299Giy (rs4986790) Thr399Ile (rs4986791) NS Pain (P = 0.02) DAS, HAQ, Sharp score: NS Sanchez et al. (2004) Spain (E) 222 1199 <i>TLR4</i> : Asp299Giy (rs4986790), Thr399Ile (rs4986791) NS Pain (P = 0.025) DAS, HAQ, Sharp score: NS Sanchez et al. (2004) Spain (E) 222 1199 <i>TLR4</i> : Asp299Giy (rs4986790), Thr399Ile (rs4986791) NS Pain (P = 0.025) DAS, HAQ, Sharp score: NS Sanchez et al. (2004) Spain (E) 222 1199 <i>TLR4</i> : Asp299Giy (rs4986790), Thr399Ile (rs4986791) NS Pain (P = 0.025) PAS, HAQ, Sharp score: NS Sanchez et al. (2004) Spain (E) 222 314 <i>TLR4</i> : Asp299Giy (rs4986790), Thr399Ile (rs4986791) NS Pain (P = 0.025) PAS, HAQ, Sharp score: NS Sanchez et al. (2004) Spain (E) 222 879 <i>TLR4</i> : Asp299Giy (rs4986790) NS Pain (P = 0.025) PAS, HAQ, Sharp score: NS Sanchez et al. (2003) UK (E) 212 879 <i>TLR4</i> : Asp299Giy (rs4986790) NS Pain (P = 0.025) PAS, HAQ, Sharp score: NS Riddeng et al. (2003) UK (E) 212 879 <i>TLR4</i> : Asp299Giy (rs4986790) NS PAS et al. (2004) PAS et al. (2005) PAS et					rs4696480; <i>TLR4</i> : rs2737191, rs4986790, rs1554973; <i>TLR6</i> : rs5743810; <i>TLR9</i> : rs187084, rs352140		
Kang and Lee (2007)Korea (A)4480 $TLR4$ : Asp299Giy (rs4986790), Thr399IIe (rs4986791)None polymorphisms detectedNALee et al. (2006)Korea (A)183148 $7LR4$ : Asp299Giy (rs4986790)NANAKulliala et al. (2006)Finland (E)1690 $7LR4$ : Asp299Giy (rs4986790)NAAssociation with rapid responseKulliala et al. (2004)Netherlands (E)282314 $7LR4$ : Asp299Giy (rs4986790)NAAssociation (P = 0.02)Radstake et al. (2004)Spain (E)224199 $7LR4$ : Asp299Giy (rs4986790)NSAssociation (P = 0.025)DAS, HAQ. Sharp score: NSSanchez et al. (2004)Spain (E)224199 $7LR4$ : Asp299Giy (rs4986790), Thr399IIe (rs4986791)NSAssociation (P = 0.025)DAS, HAQ. Sharp score: NSSanchez et al. (2004)Spain (E)212879 $7LR4$ : Asp299Giy (rs4986790), Thr399IIe (rs4986791)NSImated epitope, RF; rheumatoidSanchez et al. (2004)Spain (E)212879 $7LR4$ : Asp299Giy (rs4986790), NSAssociation (P = 0.025)DAS, HAQ. Sharp score: NSSanchez et al. (2003)UK (E)212879 $7LR4$ : Asp299Giy (rs4986790)NSShared epitope: RF; rheumatoidRA = rheumatoidNSNSNSNSShared epitope: NSShared epitope: NSRA = rheumatoid arthritis; TLR = Toll-like receptor; T = Turkish; A = Asian; E = European; UK = United Kingdom; SNP = single nucleotide polymorphism; NAA = end available; NS = NS = not significant; DAZS28 elisease activity score 28; RF = rheumatoid factor;	Sheedy et al. (2008)	UK (E)	964	961	<i>TLR4</i> : Asp299Gly (rs4986790)	NS	RF, anti-CCP: NS
Lee et al. (2006) Korea (A) 183 148 7LR2: guanine-thymine repeats S allele <sup>b</sup> (P = 0.03) NA sociation with rapid response Kuliala et al. (2006) Finland (E) 169 0 7LR4: Asp299Gly (rs4986790) NA Association (P = 0.02) NA sociation with rapid response (D AS28) (P = 0.002) (D AS28) (P = 0.002) Sanchez et al. (2004) Netherlands (E) 282 314 7LR4: Asp299Gly (rs4986790) Thr399Ile (rs4986791) NS Association (P = 0.025) DAS, IAAO, Shared epitope, RF, rheumatoid anchez et al. (2004) Spain (E) 224 199 7LR4: Asp299Gly (rs4986790), Thr399Ile (rs4986791) NS Association (P = 0.025) DAS, IAAO, Shared epitope, RF, rheumatoid anchez et al. (2004) Spain (E) 224 199 7LR4: Asp299Gly (rs4986790), Thr399Ile (rs4986791) NS Association (P = 0.025) TAR4 expresses, fielding et al. (2003) UK (E) 212 879 7LR4: Asp299Gly (rs4986790), NS Shared epitope, RF, rheumatoid anchez et al. (2003) UK (E) 212 879 7LR4: Asp299Gly (rs4986790) NS NS Shared epitope, RF, rheumatoid anchez et al. (2003) UK (E) 212 879 7LR4: Asp299Gly (rs4986790) NS Shared epitope, RF, rheumatoid for an orbit of the receptor; T = Turkish; A = Asian; E = European; UK = United Kingdom; SNP = single nucleotide polymorphism; NA exacense to constitute the orbit with $< (CTT)$	Kang and Lee (2007)	Korea (A)	4	80	TLR4: Asp299Gly (rs4986790), Thr399Ile (rs4986791)	None polymorphisms detected	NA
Kuuliala et al. (2006) Finland (E) 169 0 7 <i>LR4</i> : Asp299Gly (rs4986790) NA Association with rapid response (DAS28) (P = 0.002) (DAS, HAQ, Sharp score: NS sanchez et al. (2004) Spain (E) 224 199 7 <i>LR4</i> : Asp299Gly (rs4986790), Thr399Ile (rs4986791) NS Association (P = 0.025) DAS, HAQ, Sharp score: NS sanchez et al. (2004) Spain (E) 224 199 7 <i>LR4</i> : Asp299Gly (rs4986790), Thr399Ile (rs4986791) NS Association (P = 0.025) DAS, HAQ, Shared epitope, RF, rheumatoid nodules, extra-articular disease, female, onset age: NS Astronaction (E) 212 879 7 <i>LR4</i> : Asp299Gly (rs4986790), Thr399Ile (rs4986791) NS Association (P = 0.025) DAS, HAQ, Shared epitope, RF, rheumatoid arthritis; TLR = 7011-like receptor; T = Turkish; A = Asian; E = European; UK = United Kingdom; SNP = single nucleotide polymorphism; NA = not available; = NS = not significant; DAS28 = disease activity score 28; RF = rheumatoid factor; anti-cyclic citrullinated peptide; HAQ = Health A conservent Outer (Outer CPP = anti-cyclic citrullinated peptide; HAQ = Health A conservent Outer commonent with $< (GT)$ .	Lee et al. (2006)	Korea (A)	183	148	TLR2: guanine-thymine repeats	S allele <sup>b</sup> ( $P = 0.03$ )	NA
Radstake et al. (2004) Netherlands (E) 282 314 $7LR4$ : Asp299Gly (rs4986790) Association (P = 0.025) DAS, HAO, Sharp score: NS Sanchez et al. (2004) Spain (E) 224 199 $7LR4$ : Asp299Gly (rs4986790), Thr399Ile (rs4986791) NS DAS, HAO, Sharp score: NS Shared epitope, RF, rheumatoid nodules, extra-articular disease, female, onset age: NS Shared epitope, RS in the conset age: NS Shared epitope, SN Shared epi	Kuuliala et al. (2006)	Finland (E)	169	0	<i>TLR4</i> : Asp299Gly (rs4986790)	NA	Association with rapid response
Radstake et al. (2004) Netherlands (E) 282 314 7LR4: Asp299Gly (rs4986790), Thr399lle (rs4986791) NS Association (P = 0.025) DAS, HAQ, Sharp score: NS Sauchez et al. (2004) Spain (E) 224 199 7LR4: Asp299Gly (rs4986790), Thr399lle (rs4986791) NS Instruct and the problem of the matatoid nodules, extra-articular disease, female, onset age: NS (readile, onset age: NS 212 879 7LR4: Asp299Gly (rs4986790), Thr399lle (rs4986791) NS (rs4986791) NS (rs4986791) Shared epitope, RF, thermatoid nodules, extra-articular disease, female, onset age: NS (rs4012) UK (E) 212 879 7LR4: Asp299Gly (rs4986790) NS (rs4986790) NS (rs4986790) Shared epitope, NS (rs4012) and disease, female, onset age: NS (rs4012) UK (E) 212 879 7LR4: Asp299Gly (rs4986790) NS (rs4012) (rs4012							(DAS28) (P = 0.002)
Sanchez et al. (2004) Spain (E) 224 199 <i>TLR4</i> : Asp299Giy (rs4986790), Th:399Ile (rs4986791) NS Shared epitope, RF, rheumatoid noble is extra-articular disease, female or an endules, extra-articular disease, female or artex articular disease, and the end of the e	Radstake et al. (2004)	Netherlands (E)	282	314	<i>TLR4</i> : Asp299Gly (rs4986790)	Association ( $P = 0.025$ )	DAS, HAQ, Sharp score: NS
Kilding et al. (2003) UK (E) 212 879 7LR4: Asp299Gly (rs4986790) NS remale, onset age: NS   RA = rheumatoid arthritis; TLR = Toll-like receptor; T = Turkish; A = Asian; E = European; UK = United Kingdom; SNP = single nucleotide polymorphism; NA   = not available; = NS = not significant; DAS28 = disease activity score 28; RF = rheumatoid factor; anti-CCP = anti-cyclic citrullinated peptide; HAQ = Health	Sanchez et al. (2004)	Spain (E)	224	199	TLR4: Asp299Gly (rs4986790), Thr399Ile (rs4986791)	NS	Shared epitope, RF, rheumatoid
Kilding et al. (2003) UK (E) 212 879 $TLR$ 4. Asp299Gly (rs4986790) NS Shared epitometor devices rescaled to the state of							famules, extra-articular disease,
Kilding et al. (2003) UK (E) 212 879 7LR4: Asp299Gly (rs4986790) NS Shared epitope: NS Shared epitope: NS Shared epitope: NS $R = rheumatoid arthritis; TLR = Toll-like receptor; T = Turkish; A = Asian; E = European; UK = United Kingdom; SNP = single nucleotide polymorphism; NA = not available; = NS = not significant; DAS28 = disease activity score 28; RF = rheumatoid factor; anti-CCP = anti-cyclic citrullinated peptide; HAQ = Health A concorrect Outset Outset$							ICILIAIC, UIDCI ABC. IND
RA = rheumatoid arthritis; TLR = Toll-like receptor; T = Turkish; A = Asian; E = European; UK = United Kingdom; SNP = single nucleotide polymorphism; NA = not available; = NS = not significant; DAS28 = disease activity score 28; RF = rheumatoid factor; anti-CCP = anti-cyclic citrullinated peptide; HAQ = Health	Kilding et al. (2003)	UK (E)	212	879	<i>TLR4</i> : Asp299Gly (rs4986790)	NS	Shared epitope: NS
	RA = rheumatoid a = not available; = ]	urthritis; TLR = Tol NS = not significar	II-like nt; DA	receptor: S28 = di	The Turkish; $A = Asian$ ; $E = European$ ; $UK = Un$ ( $T = The transform of the transform o$	nited Kingdom; SNP = sing anti-CCP = anti-cyclic citru	le nucleotide polymorphism; ullinated peptide; HAQ = He

Genetics and Molecular Research 12 (1): 328-334 (2013)

Y.H. Lee et al.

Study name	Statistics for each study						Odds ratio and 95%CI					
	Odds ratio	Lower limit	Upper limit	Z-value	P value							
Sheedy, 2008	0.898	0.690	1.168	-0.802	0.422	1	1	1			1	1
Radskate, 2004	0.673	0.424	1.068	-1.679	0.093			-+-	⊢-			
Kilding, 2003	1.135	0.745	1.729	0.589	0.556					-1		
	0.897	0.734	1.096	-1.061	0.289				٠			
						0.1	0.2	0.5	1	2	5	10
							Control			RA		

**Figure 1.** Odds ratio and 95% confidence interval (95%CI) of individual studies and pooled data for the 2 vs 1 *TLR4* Asp299Gly (rs4986790) polymorphism allele comparison with respect to rheumatoid arthritis (RA) susceptibility in Europeans.

The aim of the case-only study, which was performed with 169 RA patients by Kuuliala et al. (2006), was to determine whether the *TLR4* Asp299Gly (rs4986790) polymorphism influences treatment response. The authors found that DAS28 was significantly different in RA patients with and those without this polymorphism who were treated with a disease-modifying anti-rheumatic drug (P = 0.019) but not between RA patients with and those without this polymorphism treated with 3 disease-modifying anti-rheumatic drugs and prednisolone (P = 0.31).

## DISCUSSION

Viruses and bacteria are known to increase RA susceptibility and exacerbate RA by binding to TLRs (Drexler and Foxwell, 2010). Furthermore, TLRs have been suggested to play a role in responses to pathogens in RA based on findings obtained in animal models of arthritis in which bacterial cell wall components were used to induce experimental arthritis (Cromartie et al., 1977). In addition, *TLR2*, *3*, *4*, *7*, and *9* are expressed in human RA synovial tissues (Radstake et al., 2004). Given the known genetic predisposition displayed in RA patients (Choi et al., 2006; Moon et al., 2010), *TLR* polymorphism studies have been conducted to determine whether TLR is involved in the pathogenesis of RA.

In the present study, we undertook a systematic review and meta-analysis of associations between *TLR* polymorphisms and RA in terms of disease susceptibility and severity. Some polymorphisms have been shown to be associated with susceptibility and clinical findings, but only 1 study has been conducted to date on each of these associations. For example, a significant difference in *TLR9* rs187084 allele frequencies was found between Turkish RA patients and controls. Etem et al. (2011) found a moderate association between rheumatoid factor and *TLR8* rs5741883, and an increased S allele frequency in RA patients. However, no confirmatory study has been conducted to date.

The *TLR4* Asp299Gly (rs4986790) polymorphism is the most frequently studied polymorphism in RA, and it displays ethnic differences. Africans have the highest frequency (16%) (Mockenhaupt et al., 2006), followed by Europeans (4-10%) (Adam et al., 2006), whereas Asians do not have this polymorphism (Zheng et al., 2010). In the present study,

Genetics and Molecular Research 12 (1): 328-334 (2013)

meta-analysis of the *TLR4* Asp299Gly polymorphism failed to reveal any association with RA susceptibility in Europeans. The single case-only study found that DAS28 differed significantly in RA patients according to the presence of this polymorphism (Kuuliala et al., 2006), but the 3 case-control studies failed to identify an association between this polymorphism and the clinical characteristics of RA (Kilding et al., 2003; Radstake et al., 2004; Sheedy et al., 2008).

The present study has some limitations. First, the number of studies included in the systematic review might have been too small to detect slight associations within ethnic groups. Second, our meta-analysis included data from European patients, and thus, our results are applicable only to this ethnic group. Furthermore, only 3 studies were conducted in Europeans (Kilding et al., 2003; Radstake et al., 2004; Sheedy et al., 2008), which may mean that our investigation was underpowered (Sung et al., 2009; Wang et al., 2010).

Although we found no major contribution of *TLR* polymorphisms to RA, our results suggest that the *TLR* polymorphism is associated with the development and clinical characteristics of RA. However, because only a relatively small number of studies have investigated the roles of *TLR* polymorphisms in the pathogenesis of RA, further research is required to determine whether the polymorphisms of *TLR* contribute to RA susceptibility and severity.

## ACKNOWLEDGMENTS

Research supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (#A102065).

#### **Conflict of interest statement**

We have no financial conflicts of interest.

#### REFERENCES

- Adam R, Sturrock RD and Gracie JA (2006). TLR4 mutations (Asp299Gly and Thr399Ile) are not associated with ankylosing spondylitis. Ann. Rheum. Dis. 65: 1099-1101.
- Choi SJ, Rho YH, Ji JD, Song GG, et al. (2006). Genome scan meta-analysis of rheumatoid arthritis. *Rheumatology* 45: 166-170.
- Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, et al. (1977). Arthritis in rats after systemic injection of streptococcal cells or cell walls. J. Exp. Med. 146: 1585-1602.
- Deighton CM, Walker DJ, Griffiths ID and Roberts DF (1989). The contribution of HLA to rheumatoid arthritis. *Clin. Genet.* 36: 178-182.
- Drexler SK and Foxwell BM (2010). The role of toll-like receptors in chronic inflammation. *Int. J. Biochem. Cell Biol.* 42: 506-518.
- Enevold C, Radstake TR, Coenen MJ, Fransen J, et al. (2010). Multiplex screening of 22 single-nucleotide polymorphisms in 7 Toll-like receptors: an association study in rheumatoid arthritis. *J. Rheumatol.* 37: 905-910.
- Etem EO, Elyas H, Ozgocmen S, Yildirim A, et al. (2011). The investigation of toll-like receptor 3, 9 and 10 gene polymorphisms in Turkish rheumatoid arthritis patients. *Rheumatol. Int.* 31: 1369-1374.
- Hurst J and von Landenberg P (2008). Toll-like receptors and autoimmunity. Autoimmun. Rev. 7: 204-208.
- Jaen O, Petit-Teixeira E, Kirsten H, Ahnert P, et al. (2009). No evidence of major effects in several Toll-like receptor gene polymorphisms in rheumatoid arthritis. Arthritis Res. Ther. 11: R5.
- Kang ES and Lee J (2007). Genotypic analysis of Asp299Gly and Thr399IIe polymorphism of Toll-like receptor 4 in systemic autoimmune diseases of Korean population. *Rheumatol. Int.* 27: 887-889.
- Kilding R, Akil M, Till S, Amos R, et al. (2003). A biologically important single nucleotide polymorphism within the tolllike receptor-4 gene is not associated with rheumatoid arthritis. *Clin. Exp. Rheumatol.* 21: 340-342.

©FUNPEC-RP www.funpecrp.com.br

Genetics and Molecular Research 12 (1): 328-334 (2013)

- Lee EY, Yim JJ, Lee HS, Lee YJ, et al. (2006). Dinucleotide repeat polymorphism in intron II of human Toll-like receptor 2 gene and susceptibility to rheumatoid arthritis. *Int. J. Immunogenet.* 33: 211-215.
- Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, et al. (2006). Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. *Proc. Natl. Acad. Sci. U. S. A.* 103: 177-182.
- Moon SJ, Park MK, Oh HJ, Lee SY, et al. (2010). Engagement of toll-like receptor 3 induces vascular endothelial growth factor and interleukin-8 in human rheumatoid synovial fibroblasts. *Korean J. Intern. Med.* 25: 429-435.
- Radstake TR, Franke B, Hanssen S, Netea MG, et al. (2004). The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum. 50: 999-1001.
- Roelofs MF, Abdollahi-Roodsaz S, Joosten LA, van den Berg WB, et al. (2008). The orchestra of Toll-like receptors and their potential role in frequently occurring rheumatic conditions. *Arthritis Rheum*. 58: 338-348.
- Sanchez E, Orozco G, Lopez-Nevot MA, Jimenez-Alonso J, et al. (2004). Polymorphisms of toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus. *Tissue Antigens* 63: 54-57.
- Sheedy FJ, Marinou I, O'Neill LA and Wilson AG (2008). The Mal/TIRAP S180L and TLR4 G299D polymorphisms are not associated with susceptibility to, or severity of, rheumatoid arthritis. Ann. Rheum. Dis. 67: 1328-1331.
- Sung IH, Kim TH, Bang SY, Kim TJ, et al. (2009). IL-23R polymorphisms in patients with ankylosing spondylitis in Korea. J. Rheumatol. 36: 1003-1005.
- Takeda K, Kaisho T and Akira S (2003). Toll-like receptors. Annu. Rev. Immunol. 21: 335-376.
- Wang X, Huang J, Lin Z, Liao Z, et al. (2010). Single-nucleotide polymorphisms and expression of IL23R in Chinese ankylosing spondylitis patients. *Rheumatol. Int.* 30: 955-959.
- Wordsworth P and Bell J (1991). Polygenic susceptibility in rheumatoid arthritis. Ann. Rheum. Dis. 50: 343-346.
- Zheng B, Li Q, Wei C, Qin J, et al. (2010). Lack of association of TLR4 gene Asp299Gly and Thr399Ile polymorphisms with rheumatoid arthritis in Chinese Han population of Yunnan Province. *Rheumatol. Int.* 30: 1249-1252.

Kuuliala K, Orpana A, Leirisalo-Repo M, Kautiainen H, et al. (2006). Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis. *Ann. Rheum. Dis.* 65: 1241-1243.

Genetics and Molecular Research 12 (1): 328-334 (2013)